Adaptive Biotechnologies director Owen sells $249,990 in stock.

Owen, a director at Adaptive Biotechnologies, sold 9,615 shares of the company's stock on August 26, 2026. The sale was for $249,990, with each share priced at $26.00. This transaction occurred as the stock price neared its highest point in the past 52 weeks, at $26.87. ADPT had experienced a significant 89% growth over the previous year.

However, InvestingPro analysis suggests the stock is overvalued at its current price point, with limited potential for further gains. Following this sale, Ms. Owen now owns 78,639 shares of Adaptive Biotechnologies. Investors can find more detailed analysis of ADPT's valuation and performance through the Pro Research Report provided by InvestingPro.

In other news, Adaptive Biotechnologies reported a loss of $0.25 per share in their second-quarter earnings, which was lower than the estimated loss of $0.14 per share. However, the company's revenue of $71.6 million exceeded analyst expectations, showing a 22% increase from the previous year's $58.7 million. Analysts Guggenheim and BTIG have raised their price targets for Adaptive Biotechnologies to $25, reflecting confidence in the company's performance.

The company's clonoSEQ MRD test franchise experienced a 43% growth in volumes year-over-year, indicating continued interest in their products.